SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

NeuroThera, a SciSparc subsidiary, is broadening U.S. patent coverage for PEA-based combinations with psychedelic compounds through its collaboration with Clearmind.

Rhea-AI Summary

SciSparc (SPRC)/b) reported that subsidiary Three U.S. patent applications have been published for combinations of lysergic acid diethylamide (LSD), ketamine and ibogaine with N‑acylethanolamines, including NeuroThera’s proprietary palmitoylethanolamide (PEA) technology. The filings describe potential therapeutic uses across mental health conditions such as depression and post‑traumatic stress disorder (PTSD), as well as pain and substance use disorders.

These applications build on a previously announced U.S. patent application for combinations of MDMA and N‑acylethanolamines targeting PTSD, anxiety and eating disorders. NeuroThera states that the maturing patent portfolio illustrates broader potential applications of its PEA technology with psychedelic compounds, and that the collaboration with Clearmind is intended to support development of safer, more effective treatments for common and growing mental‑health and substance use conditions.

Market Context

The March 12 collaboration patent announcement coincided with a 22.86% reaction, while the November ...

Analysis

The March 12 collaboration patent announcement coincided with a 22.86% reaction, while the November 20 filing coincided with -4.47%; these prior Clearmind patent disclosures showed mixed market responses, not a directional precedent for the newly published U.S. applications.

Key Figures

U.S. patent applications published: 3 applications

U.S. patent applications published

3 applications

NeuroThera-Clearmind collaboration

Previous Partnership Reports

2 past events · Latest: Mar 12

Same Type 2 events

1. Mar 12

   Patent application

   24h Move

   +22.9%

   NeuroThera-Clearmind published a PCT patent application for MEAI–PEA weight-loss and fatty-liver treatment.

2. Nov 20

   Patent application

   24h Move

   -4.5%

   NeuroThera filed an Israeli patent application for MEAI and N-acylethanolamines targeting depression.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

n-acylethanolamines, palmitoylethanolamide

2 terms

n-acylethanolamines medical

"novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines"

N-acylethanolamines are a family of naturally occurring fatty molecules that act as small chemical messengers inside the body, helping cells communicate about inflammation, appetite, pain and other processes. Investors care because these molecules can be targets or biomarkers for drugs, diagnostics and wellness products — like a visible readout on a dashboard that indicates whether a treatment is working or a condition is present — which affects clinical development, regulatory approval and market potential.

palmitoylethanolamide medical

"including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology."

Palmitoylethanolamide (PEA) is a naturally occurring fatty molecule produced in the body and sold as a supplement or experimental therapy for reducing pain and inflammation; think of it as a built‑in calming signal that helps quiet irritated tissues. Investors watch PEA because its potential medical benefits, regulatory path (supplement vs. drug), and clinical evidence drive market demand, pricing and the risk/reward of companies developing or selling PEA-based products — similar to how a promising ingredient can change the fortunes of a consumer brand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND).

As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology.

The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.

These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds such as psychedelic compounds. NeuroThera believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications.

NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions. The companies remain focused on combining PEA with psychedelic‑derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential therapeutic uses of NeuroThera’s product candidates across a range of indications, the broader potential applications of NeuroThera’s PEA technology, the potential of NeuroThera and Clearmind to bring safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions, and continued enhancement of the intellectual property portfolio supporting these innovative therapeutics.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055